ANTONIO DA SILVA COELHO NETTO, M.D.; BERNARDO LÉO WAJCHENBERG, M.D.; CASSIO RAVAGLIA, M.D.; VIRGILIO GONÇALVES PEREIRA, M.D.; JOSÉ SHNAIDER, M.D.; ARMANDO AGUIAR PUPO, M.D.; ANTONIO BARROS DE ULHOA CINTRA, M.D., PH.D.
The initial observations of Nelson and Woodward (1, 2) that the feeding of the insecticide, 1,1-dichloro-2,2-bis (p-chlorophenyl) ethane (DDD) to dogs results in necrosis and atrophy of the adrenal cortex opened a new research field for adrenocorticolytic drugs. Brown et al. (3-5) observed that necrosis of the adrenal cortex was followed by a decrease in urinary excretion of 17-hydroxycorticosteroids. In these animals a picture compatible with adrenocortical insufficiency developed which was not modified by the simultaneous administration of adrenocorticotropic hormone (ACTH) but which could be prevented by cortisone.
Other authors (6-8) confirmed these initial data and the technical grade DDD
DA SILVA COELHO NETTO A, WAJCHENBERG BL, RAVAGLIA C, PEREIRA VG, SHNAIDER J, PUPO AA, et al. Treatment of Adrenocortical Cancer with O,P′-DDD. Ann Intern Med. ;59:74–78. doi: 10.7326/0003-4819-59-1-74
Download citation file:
Published: Ann Intern Med. 1963;59(1_Part_1):74-78.
Adrenal Disorders, Endocrine and Metabolism, Endocrine Cancer, Hematology/Oncology.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use